This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up
by Zacks Equity Research
Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.
What's in Store for Vericel (VCEL) This Earnings Season?
by Zacks Equity Research
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
Bull or Bear: Your Investment Strategy for 2019
by Sejuti Banerjea
Whether you're a bull or a bear, it may be a good idea to go defensive about now.
Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise
by Zacks Equity Research
Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise
4 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VCEL) Outperforming Other Medical Stocks This Year?
5 Nasdaq Composite Stocks That Braved the Index's Bloodbath
by Nalak Das
Despite a plummeting Nasdaq Composite, a few companies have survived the turbulence because of their internal strengths.
4 Healthcare Stocks That Popped More Than 100% in 2018
by Sapna Bagaria
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk
by Zacks Equity Research
Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk
4 Best Stocks That Flaunt Superb Earnings Acceleration
by Tirthankar Chakraborty
Studies show that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
Vericel (VCEL) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Vericel (VCEL) closed the most recent trading day at $17.10, making no change from the previous trading session.
Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VCEL) Outperforming Other Medical Stocks This Year?
Small-Cap ETFs & Stocks to Outperform This Holiday Season (Revised)
by Sweta Killa
The outperformance of the small-caps seems to hold true this year given that these pint-sized stocks are well insulated from international headwinds.
Zacks.com highlights: Helen of Troy, Vericel, Mobile Mini and Logitech International
by Zacks Equity Research
Zacks.com highlights: Helen of Troy, Vericel, Mobile Mini and Logitech International
4 Best Stocks to Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that a majority of successful stocks had seen acceleration in earnings before an uptick in the stock price.
Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
by Zacks Equity Research
Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
The Zacks Analyst Blog Highlights: Vericel, Malibu Boats, Upland Software, QuinStreet and eGain
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vericel, Malibu Boats, Upland Software, QuinStreet and eGain
Small-Cap ETFs & Stocks to Outperform This Holiday Season
by Sweta Killa
The outperformance of the small-caps seems to hold true this year given that these pint-sized stocks are well insulated from international headwinds.
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Top Ranked Momentum Stocks to Buy for November 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
Will Vericel (VCEL) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Vericel Corporation (VCEL).